ReviewCancer innovation2026
Radioiodine-Refractory Differentiated Thyroid Cancer: Definition, Molecular Mechanisms, and Advances in Precision Therapy.
Review in Cancer innovation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radioiodine-refractory differentiated thyroid cancer, defined by loss of responsiveness to ¹³¹I therapy or by heterogeneous iodine uptake, accounts for the majority of thyroid cancer-related deaths; 10-year survival is approximately 10% with distant metastases. Its definition is not uniform: the 2014 expert consensus and the 2015 American Thyroid Association guideline diverge on heterogeneous uptake and on progression despite substantial uptake, and the 2019 Martinique principles reframe these as risk-stratification triggers rather than absolute disqualifiers. Refractoriness reflects mitogen-activated protein kinase-driven silencing of the sodium iodide symporter;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.